{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:09:32Z","timestamp":1793506172795,"version":"4.5.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dx-2025-0012_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Biomarkers are useful clinical tools but only a handful of them are used routinely for patient care. Despite intense efforts to discover new, clinically useful biomarkers, very few new circulating biomarkers were implemented in clinical practice in the last 40\u00a0years. This is mainly due to rather poor clinical performance. Here, our goal was to validate the performance of a group of newly discovered circulating biomarkers for glioma by comparing our data with data from a paper recently published in Science Advances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dx-2025-0012_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed our own sets of clinical samples (gliomas (n=30), meningiomas (n=20)) and a different analytical assay (Proximity Extension Assay, OLINK Proteomics) to compare the results of Shen and colleagues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dx-2025-0012_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite the sophistication of the utilized discovery method by the original investigators, we found that the newly proposed biomarkers for glioma (the best one presumably being SERPINA6) did not perform as originally claimed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dx-2025-0012_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Scientific irreproducibility has been extensively discussed in the literature. A large proportion of newly discovered candidate biomarkers likely represent \u201cfalse discovery\u201d and significantly contribute to the propagation of irreproducible results between investigators. One of the best ways to assess the value of any new biomarker is by independent and extensive validation. Based on our previous classification of irreproducible results, we believe that this new work likely represents another example of biomarker false discovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dx-2025-0012","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T01:31:39Z","timestamp":1743125499000},"page":"464-469","source":"Crossref","is-referenced-by-count":1,"title":["Validation of new, circulating biomarkers for gliomas"],"prefix":"10.1515","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-8315","authenticated-orcid":false,"given":"Miyo K.","family":"Chatanaka","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Avery","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Dalla Lana School of Public Health , University of Toronto , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-820X","authenticated-orcid":false,"given":"Eleftherios P.","family":"Diamandis","sequence":"additional","affiliation":[{"name":"518775 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025121206492421338_j_dx-2025-0012_ref_001","doi-asserted-by":"crossref","unstructured":"Shen, L, Zhang, Z, Wu, P, Yang, J, Cai, Y, Chen, K, et al.. Mechanistic insight into glioma through spatially multidimensional proteomics. Sci Adv 2024;10:eadk1721. https:\/\/doi.org\/10.1126\/sciadv.adk1721.","DOI":"10.1126\/sciadv.adk1721"},{"key":"2025121206492421338_j_dx-2025-0012_ref_002","doi-asserted-by":"crossref","unstructured":"Fiala, C, Diamandis, EP. A multi-cancer detection test: focus on the positive predictive value. Ann Oncol 2020;31:1267\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.028.","DOI":"10.1016\/j.annonc.2020.05.028"},{"key":"2025121206492421338_j_dx-2025-0012_ref_003","doi-asserted-by":"crossref","unstructured":"Diamandis, EP, Li, M. The side effects of translational omics: overtesting, overdiagnosis, overtreatment. Clin Chem Lab Med 2016;54:389\u201396. https:\/\/doi.org\/10.1515\/cclm-2015-0762.","DOI":"10.1515\/cclm-2015-0762"},{"key":"2025121206492421338_j_dx-2025-0012_ref_004","doi-asserted-by":"crossref","unstructured":"Fiala, C, Taher, J, Diamandis, EP. P4 medicine or O4 medicine? Hippocrates provides the answer. J\u00a0Appl Lab Med 2019;4:108\u201319. https:\/\/doi.org\/10.1373\/jalm.2018.028613.","DOI":"10.1373\/jalm.2018.028613"},{"key":"2025121206492421338_j_dx-2025-0012_ref_005","doi-asserted-by":"crossref","unstructured":"Chen, M, Ren, AH, Prassas, I, Soosaipillai, A, Lim, B, Fraser, DD, et al.. Plasma protein profiling by proximity extension assay technology reveals novel biomarkers of traumatic brain injury-a pilot study. J\u00a0Appl Lab Med 2021;6:1165\u201378. https:\/\/doi.org\/10.1093\/jalm\/jfab004.","DOI":"10.1093\/jalm\/jfab004"},{"key":"2025121206492421338_j_dx-2025-0012_ref_006","doi-asserted-by":"crossref","unstructured":"Ren, AH, Diamandis, EP, Kulasingam, V. Uncovering the depths of the human proteome: antibody-based technologies for ultrasensitive multiplexed protein detection and quantification. Mol Cell Proteomics MCP 2021;20:100155. https:\/\/doi.org\/10.1016\/j.mcpro.2021.100155.","DOI":"10.1016\/j.mcpro.2021.100155"},{"key":"2025121206492421338_j_dx-2025-0012_ref_007","doi-asserted-by":"crossref","unstructured":"Ren, A, Prassas, I, Sugumar, V, Soosaipillai, A, Bernardini, M, Diamandis, EP, et al.. Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. F1000Research 2021;10:509. https:\/\/doi.org\/10.12688\/f1000research.53364.1.","DOI":"10.12688\/f1000research.53364.1"},{"key":"2025121206492421338_j_dx-2025-0012_ref_008","doi-asserted-by":"crossref","unstructured":"Ghorbani, A, Avery, LM, Sohaei, D, Soosaipillai, A, Richer, M, Horbinski, C, et al.. Discovery of novel glioma serum biomarkers by proximity extension assay. Clin Proteom 2023;20:12. https:\/\/doi.org\/10.1186\/s12014-023-09400-5.","DOI":"10.1186\/s12014-023-09400-5"},{"key":"2025121206492421338_j_dx-2025-0012_ref_009","doi-asserted-by":"crossref","unstructured":"Sturgeon, CM, Duffy, MJ, Stenman, UH, Lilja, H, Br\u00fcnner, N, Chan, DW, et al.. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11\u201379. https:\/\/doi.org\/10.1373\/clinchem.2008.105601.","DOI":"10.1373\/clinchem.2008.105601"},{"key":"2025121206492421338_j_dx-2025-0012_ref_010","doi-asserted-by":"crossref","unstructured":"Diamandis, EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med 2012;10:87. https:\/\/doi.org\/10.1186\/1741-7015-10-87.","DOI":"10.1186\/1741-7015-10-87"},{"key":"2025121206492421338_j_dx-2025-0012_ref_011","doi-asserted-by":"crossref","unstructured":"Diamandis, EP. Cancer biomarkers: can we turn recent failures into success? JNCI J Natl Cancer Inst 2010;102:1462\u20137. https:\/\/doi.org\/10.1093\/jnci\/djq306.","DOI":"10.1093\/jnci\/djq306"},{"key":"2025121206492421338_j_dx-2025-0012_ref_012","doi-asserted-by":"crossref","unstructured":"Diamandis, EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J\u00a0Natl Cancer Inst 2004;96:353\u20136. https:\/\/doi.org\/10.1093\/jnci\/djh056.","DOI":"10.1093\/jnci\/djh056"},{"key":"2025121206492421338_j_dx-2025-0012_ref_013","doi-asserted-by":"crossref","unstructured":"Ransohoff, DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142\u20139. https:\/\/doi.org\/10.1038\/nrc1550.","DOI":"10.1038\/nrc1550"},{"key":"2025121206492421338_j_dx-2025-0012_ref_014","doi-asserted-by":"crossref","unstructured":"Ioannidis, JPA. Discussion: why \u201can estimate of the science-wise false discovery rate and application to the top medical literature\u201d is false. Biostat Oxf Engl. 2014;15:28\u201336. discussion 39-45. https:\/\/doi.org\/10.1093\/biostatistics\/kxt036.","DOI":"10.1093\/biostatistics\/kxt036"},{"key":"2025121206492421338_j_dx-2025-0012_ref_015","doi-asserted-by":"crossref","unstructured":"Ioannidis, JPA. Molecular bias. Eur J Epidemiol 2005;20:739\u201345. https:\/\/doi.org\/10.1007\/s10654-005-2028-1.","DOI":"10.1007\/s10654-005-2028-1"},{"key":"2025121206492421338_j_dx-2025-0012_ref_016","doi-asserted-by":"crossref","unstructured":"Prassas, I, Brinc, D, Farkona, S, Leung, F, Dimitromanolakis, A, Chrystoja, CC, et al.. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clin Chem. 2014;60:381\u20138. https:\/\/doi.org\/10.1373\/clinchem.2013.215236.","DOI":"10.1373\/clinchem.2013.215236"},{"key":"2025121206492421338_j_dx-2025-0012_ref_017","doi-asserted-by":"crossref","unstructured":"Petricoin, EF, Ardekani, AM, Hitt, BA, Levine, PJ, Fusaro, VA, Steinberg, SM, et al.. Use of proteomic patterns in serum to identify ovarian cancer. Lancet Lond Engl 2002;359:572\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(02)07746-2.","DOI":"10.1016\/S0140-6736(02)07746-2"},{"key":"2025121206492421338_j_dx-2025-0012_ref_018","doi-asserted-by":"crossref","unstructured":"Schully, SD, Carrick, DM, Mechanic, LE, Srivastava, S, Anderson, GL, Baron, JA, et al.. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J\u00a0Natl Cancer Inst 2015;107:djv012. https:\/\/doi.org\/10.1093\/jnci\/djv012.","DOI":"10.1093\/jnci\/djv012"},{"key":"2025121206492421338_j_dx-2025-0012_ref_019","doi-asserted-by":"crossref","unstructured":"Levett, JJ, Elkaim, LM, Alotaibi, NM, Weber, MH, Dea, N, Abd-El-Barr, MM. Publication retraction in spine surgery: a systematic review. Eur Spine J 2023;32:3704\u201312. https:\/\/doi.org\/10.1007\/s00586-023-07927-7.","DOI":"10.1007\/s00586-023-07927-7"},{"key":"2025121206492421338_j_dx-2025-0012_ref_020","doi-asserted-by":"crossref","unstructured":"Ball, P. Is AI leading to a reproducibility crisis in science? Nature 2023;624:22\u20135. https:\/\/doi.org\/10.1038\/d41586-023-03817-6.","DOI":"10.1038\/d41586-023-03817-6"},{"key":"2025121206492421338_j_dx-2025-0012_ref_021","doi-asserted-by":"crossref","unstructured":"Fiala, C, Diamandis, EP. How to reduce scientific irreproducibility: the 5-year reflection. Clin Chem Lab Med 2017;55:1845\u20138. https:\/\/doi.org\/10.1515\/cclm-2017-0759.","DOI":"10.1515\/cclm-2017-0759"},{"key":"2025121206492421338_j_dx-2025-0012_ref_022","doi-asserted-by":"crossref","unstructured":"Hamilton, SR, Liu, B, Parsons, RE, Papadopoulos, N, Jen, J, Powell, SM, et al.. The molecular basis of Turcot\u2019s syndrome. N\u00a0Engl J Med 1995;332:839\u201347. https:\/\/doi.org\/10.1056\/nejm199503303321302.","DOI":"10.1056\/NEJM199503303321302"},{"key":"2025121206492421338_j_dx-2025-0012_ref_023","doi-asserted-by":"crossref","unstructured":"Kleihues, P, Ohgaki, H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999;1:44\u201351. https:\/\/doi.org\/10.1215\/s1522851798000180.","DOI":"10.1215\/S1522851798000180"},{"key":"2025121206492421338_j_dx-2025-0012_ref_024","unstructured":"Khattab, A, Monga, DK. Turcot syndrome. In: . StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2025. [cited 2025 Feb 19]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534782\/."},{"key":"2025121206492421338_j_dx-2025-0012_ref_025","unstructured":"Schneider, K, Zelley, K, Nichols, KE, Schwartz Levine, A, Garber, J. Li-fraumeni syndrome. In: Adam, MP, Feldman, J, Mirzaa, GM, Pagon, RA, Wallace, SE, Amemiya, A, editors. GeneReviews\u00ae [internet]. Seattle (WA): University of Washington, Seattle; 1993. [cited 2025 Feb 19]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1311\/."}],"container-title":["Diagnosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2025-0012\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2025-0012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:12:16Z","timestamp":1765523536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2025-0012\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,8,7]]}},"alternative-id":["10.1515\/dx-2025-0012"],"URL":"https:\/\/doi.org\/10.1515\/dx-2025-0012","relation":{},"ISSN":["2194-802X"],"issn-type":[{"value":"2194-802X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}